Article Details

DCGI approves AstraZeneca's Lynparza for adjuvant treatment of patients with high-risk ...

Retrieved on: 2022-08-22 08:34:26

Tags for this article:

Click the tags to see associated articles and topics

DCGI approves AstraZeneca's Lynparza for adjuvant treatment of patients with high-risk .... View article details on HISWAI: https://www.expresspharma.in/dcgi-approves-astrazenecas-lynparza-for-adjuvant-treatment-of-patients-with-high-risk-early-breast-cancer/

Excerpt

DCGI approves AstraZeneca's Lynparza for adjuvant treatment of patients with high-risk early breast cancer. New data from Olympia phase-III trial ...

Article found on: www.expresspharma.in

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up